Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis <scp>C</scp>‐related liver disease and costs in <scp>A</scp>ustralia

Abstract

Considerable increases in the burden of HCV-related advanced liver disease and its complications will be seen in Australia under current treatment levels and outcomes. Introduction of improved direct-acting antiviral regimens with enhanced efficacy at current treatment levels will lead to limited impacts on this disease burden. A combination of increased treatment efficacy and greater uptake is required to achieve major reductions in advanced liver disease and related costs.